D
Ligand Pharmaceuticals Incorporated LGND
$97.80 -$5.31-5.15%
Recommendation
Sell
Prev Close
$103.11
Volume
36,027
Avg Vol (90D)
113,957
Market Cap
$1.99B
Dividend & Yield
--
52-Week Range
$67.72 - $129.90
P/E (TTM)
--
EPS (TTM)
-$0.1613
My Lists My Alerts
Rating
Reward
D+
Weak
Risk
D
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Fair
Solvency Index
Excellent
Total Return Index
Fair
Volatility Index
Weak
Dividend Index
--
Headlines
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Short Interest Update
4/4/2025 - MarketBeat
Ligand Pharmaceuticals (LGND, $103.11) entered Downtrend as Momentum indicator drops below 0 level on Apr 03, 2025
4/4/2025 - Tickeron - Stocks
Ligand Pharmaceuticals (LGND, $103.11) Moving Average Convergence Divergence (MACD) Histogram turned negative on April 3, 2025
4/4/2025 - Tickeron - Stocks
Ligand Pharmaceuticals (LGND, $105.14) entered Downtrend as Momentum indicator drops below 0 level on Mar 31, 2025
4/1/2025 - Tickeron - Technical Analysis
Ligand Pharmaceuticals (LGND, $105.14) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 31, 2025
4/1/2025 - Tickeron - Technical Analysis
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
3/31/2025 - Globe Newswire
Prudential Financial Inc. Purchases 1,360 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
3/29/2025 - Ticker Report
Loomis Sayles & Co. L P Purchases 24,921 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
3/29/2025 - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Recommendation of "Buy" from Analysts
3/27/2025 - MarketBeat
Congress Wealth Management LLC DE Purchases 4,014 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
3/25/2025 - MarketBeat
Royce & Associates LP Sells 3,193 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
3/23/2025 - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Upgraded by StockNews.com to Hold Rating
3/20/2025 - Ticker Report
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Acquired by Amundi
3/19/2025 - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Rating Increased to Hold at StockNews.com
3/18/2025 - MarketBeat
How The Parts Add Up: SLYG Targets $108
3/13/2025 - ETF Channel
Ligand Pharmaceuticals (NASDAQ:LGND) Lowered to "Sell" Rating by StockNews.com
3/13/2025 - Ticker Report
Ligand Pharmaceuticals (NASDAQ:LGND) Downgraded by StockNews.com to "Sell"
3/12/2025 - MarketBeat
LGND Crosses Below Key Moving Average Level
3/11/2025 - Market News Video
Essex Investment Management Co. LLC Sells 3,901 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
3/10/2025 - MarketBeat
Isthmus Partners LLC Sells 459 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
3/10/2025 - Ticker Report
Octavio Espinoza Sells 5,000 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock
3/8/2025 - MarketBeat
Dana Investment Advisors Inc. Sells 4,373 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
3/6/2025 - MarketBeat
Cookson Peirce & Co. Inc. Purchases 2,755 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
3/6/2025 - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Trading Down 8.8% - Here's Why
3/4/2025 - MarketBeat
Ligand Pharmaceuticals (LGND, $112.18) entered Downtrend as Momentum indicator drops below 0 level on Mar 03, 2025
3/4/2025 - Tickeron - Stocks
Income Statement
Total Revenue (TTM)
$167.13M
EBITDA (TTM)
$58.26M
EBIT (TTM)
$23.02M
Net Income (TTM)
-$4.03M
Balance Sheet
Total Assets (Q)
$941.77M
Total Debt (Q)
$7.15M
Total Liabilities (Q)
$111.34M
Book Value Per Share (Q)
$43.46
Cash Flow
Cash from Operations (TTM)
$97.05M
Cash from Investing (TTM)
-$143.66M
Cash from Financing (TTM)
$97.14M
Net Change in Cash (TTM)
$49.35M
Filings
Filing Date
Friday, February 28, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
1.33
7-Day Total Return
-9.52%
30-Day Total Return
-18.95%
60-Day Total Return
-11.34%
90-Day Total Return
-16.09%
Year to Date Total Return
-9.80%
1-Year Total Return
25.42%
2-Year Total Return
37.53%
3-Year Total Return
30.37%
5-Year Total Return
95.71%
52-week Low
Apr 22, 2024 - $67.72
52-week High
Nov 07, 2024 - $129.90
Valuation
Market Cap
$1.99B - Small Cap
Enterprise Value
$1.74B
Price/Sales (TTM)
11.71
Price/Book (Q)
2.37
Dividends and Shares
Shares Outstanding
18.97M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.ligand.com
Phone Number
858 550 7500
Address
555 Heritage Drive
Jupiter, FL 33458
Country
United States
Year Founded
1987
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL... more
NASDAQ 04/04/2025 12:37PM Eastern Quotes delayed
Weiss Ratings